Display options
Cite
Danese MD, Daumont M, Nwokeji E, et al. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data. Cancer Rep (Hoboken). 2021;e1568doi: 10.1002/cnr2.1568.
Danese, M. D., Daumont, M., Nwokeji, E., Gleeson, M., Penrod, J. R., & Lubeck, D. (2021). Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data. Cancer reports (Hoboken, N.J.), e1568. https://doi.org/10.1002/cnr2.1568
Danese, Mark D, et al. "Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data." Cancer reports (Hoboken, N.J.) vol. (2021): e1568. doi: https://doi.org/10.1002/cnr2.1568
Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data. Cancer Rep (Hoboken). 2021 Oct 26;e1568. doi: 10.1002/cnr2.1568. Epub 2021 Oct 26. PMID: 34698447.
Copy Download .nbib Format: NLM
Share it on

Cancer Rep (Hoboken). 2021 Oct 26;e1568. doi: 10.1002/cnr2.1568. Epub 2021 Oct 26.

Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.

Cancer reports (Hoboken, N.J.)

Mark D Danese, Melinda Daumont, Esmond Nwokeji, Michelle Gleeson, John R Penrod, Deborah Lubeck

Affiliations

  1. Outcomes Insights, Inc., Agoura Hills, California, USA.
  2. Bristol Myers Squibb, Princeton, New Jersey, USA.

PMID: 34698447 DOI: 10.1002/cnr2.1568

Abstract

BACKGROUND: Malignant mesothelioma is a rare neoplasm associated with asbestos exposure. Characterizing treatment patterns and outcomes of older patients with advanced malignant pleural mesothelioma (MPM) is important to understand the unmet needs of this population.

AIM: To evaluate the demographic and clinical characteristics, treatment patterns, and outcomes among older patients diagnosed with advanced MPM in the United States between 2007 and 2013.

METHODS: This was a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) data linked with Medicare claims. We included patients who were age 66 or older at the time of their primary MPM diagnosis between 2007 and 2013 and followed them through 2014. Treated patients who received first-line chemotherapy with pemetrexed and platinum within 90 days of diagnosis, second-line, or third-line therapy were identified for evaluation of outcomes.

RESULTS: There were 666 older patients with advanced MPM, of whom 82% were male, 87% White, 78% stage IV, and 70% had no mobility limitation indicators at diagnosis. There were 262 patients who received first-line chemotherapy for advanced MPM, most of whom (80%; n = 209) received pemetrexed-platinum. Of these 209 patients, 41% (n = 86) initiated second-line therapy, and 26% (n = 22) initiated third-line therapy. Median overall survival for the cohort of 209 patients was 7.2 months. Patients with epithelioid histology had better median overall survival (12.2 months) compared with other histologies (4.4-5.6 months). Within 90 days of diagnosis of advanced MPM, 78% of patients were hospitalized, 52% visited an emergency department, and 21% had hospice care. The 2-year cost of care was over $100 000 for all patients with advanced MPM treated with first-line pemetrexed-platinum.

CONCLUSIONS: Although first-line systemic anticancer treatment was generally consistent with guidelines (e.g., pemetrexed-platinum), poor patient outcomes highlight the need for effective treatment options for older patients with advanced MPM.

© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.

Keywords: Epidemiology; Surveillance; and End Results; costs; mesothelioma; overall survival; treatment

References

  1. Lemen RA. Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States. J Toxicol Environ Health B Crit Rev. 2016;19(5-6):250-265. - PubMed
  2. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17(6):525-534. - PubMed
  3. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association for the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol. 2012;7(11):1631-1639. - PubMed
  4. Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543-549. - PubMed
  5. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-1373. - PubMed
  6. Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS One. 2015;10(12):e0145039. - PubMed
  7. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5(11):1841-1848. - PubMed
  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma v2. 2020. Accessed December 2, 2020. https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. - PubMed
  9. Bristol Myers Squibb Company. OPDIVO® (Nivolumab Injection for Intravenous Use) Prescribing Information. Accessed December 2, 2020. https://packageinserts.bms.com/pi/pi_opdivo.pdf. - PubMed
  10. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. - PubMed
  11. Enewold L, Parsons H, Zhao L, et al. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020(55):3-13. - PubMed
  12. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Accessed May 18, 2021. https://seer.cancer.gov/about/factsheets/SEER_Overview.pdf. - PubMed
  13. Centers for Medicare & Medicaid Services. What's Medicare?. Accessed May 18, 2021. https://www.medicare.gov/Pubs/pdf/11306-Medicare-Medicaid.pdf. - PubMed
  14. American Joint Committe on Cancer. AJCC Cancer Staging Manual. 6th ed. Springer; 2002. - PubMed
  15. Davidoff AJ, Gardner LD, Zuckerman IH, Hendrick F, Ke X, Edelman MJ. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care. 2014;52(6):500-510. - PubMed
  16. Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35-47. - PubMed
  17. Griffiths RI, Gleeson ML, Danese MD, O'Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012;15(5):656-663. - PubMed
  18. Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:978391. - PubMed
  19. Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study. Ann Thorac Surg. 2018;105(2):432-437. - PubMed
  20. Nelson DB, Rice DC, Niu J, et al. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018;53(5):960-966. - PubMed
  21. Enewold L, Sharon E, Thomas A. Patterns of care and survival among patients with malignant mesothelioma in the United States. Lung Cancer. 2017;112:102-108. - PubMed
  22. Shavelle R, Vavra-Musser K, Lee J, Brooks J. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590. - PubMed
  23. Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-750. - PubMed

Publication Types

Grant support